Nanoparticle-mediated pulmonary drug delivery: a review.

Nanoparticle-mediated pulmonary drug delivery: a review.
复制标题

DOI:
10.3390/ijms15045852
复制
发表时间:
2014-04-08
影响因子:
5.6
通讯作者:
Müller-Goymann CC
Müller-Goymann CC
中科院分区:
生物学2区
文献类型:
--
作者:
Paranjpe M;Müller-Goymann CC

文献摘要

参考文献

被引文献

相似文献

胶体药物传递系统作为药物载体,通过不同的给药途径应用于不同的药物,已经得到了广泛的研究。系统,如固体脂质纳米颗粒,聚合物纳米颗粒和脂质体,已经研究了很长时间用于治疗各种肺部疾病。由于药物给药的非侵入性方法,用于活性药物成分(API)的局部和全身递送的肺部途径形成了API作用于肺部疾病和病症的理想环境。此外,该途径提供了许多优点,例如由于高度血管化和规避首过效应而具有快速吸收的高表面积。胶体系统的雾化或吸入目前正在被广泛研究,并且在治疗各种疾病中具有巨大的靶向药物递送潜力。此外,存在于界面处的表面活性剂相关蛋白通过降低表面张力并允许最大效果来增强这些制剂的效果。开发用于雾化的胶体系统的最具挑战性的部分是维持成功吸入的关键理化参数。下面的审查集中在目前的状态,不同的胶体系统可用于治疗各种肺部疾病沿着他们的特点。此外,还讨论了不同的体外,离体和体内细胞模型,用于测试这些系统的研究,涉及细胞培养分析。
Colloidal drug delivery systems have been extensively investigated as drug carriers for the application of different drugs via different routes of administration. Systems, such as solid lipid nanoparticles, polymeric nanoparticles and liposomes, have been investigated for a long time for the treatment of various lung diseases. The pulmonary route, owing to a noninvasive method of drug administration, for both local and systemic delivery of an active pharmaceutical ingredient (API) forms an ideal environment for APIs acting on pulmonary diseases and disorders. Additionally, this route offers many advantages, such as a high surface area with rapid absorption due to high vascularization and circumvention of the first pass effect. Aerosolization or inhalation of colloidal systems is currently being extensively studied and has huge potential for targeted drug delivery in the treatment of various diseases. Furthermore, the surfactant-associated proteins present at the interface enhance the effect of these formulations by decreasing the surface tension and allowing the maximum effect. The most challenging part of developing a colloidal system for nebulization is to maintain the critical physicochemical parameters for successful inhalation. The following review focuses on the current status of different colloidal systems available for the treatment of various lung disorders along with their characterization. Additionally, different in vitro, ex vivo and in vivo cell models developed for the testing of these systems with studies involving cell culture analysis are also discussed.
DOI: 10.1016/s0378-5173(00)00452-x
发表时间: 2000-11-04
影响因子: 5.8
作者:
Foster, KA;Avery, ML;Audus, KL
通讯作者: Audus, KL
DOI: 10.1136/thoraxjnl-2012-202230
发表时间: 2013-09-01
期刊: THORAX
影响因子: 10
作者:
Clancy, J. P.;Dupont, L.;Gupta, R.
通讯作者: Gupta, R.
DOI: 10.1093/jac/49.suppl_1.21
发表时间: 2002-02-01
影响因子: 5.2
作者:
Adler-Moore, J;Proffitt, RT
通讯作者: Proffitt, RT
DOI: 10.1016/j.ijpharm.2011.10.012
发表时间: 2012-01-17
影响因子: 5.8
作者:
Beck-Broichsitter, Moritz;Kleimann, Pia;Schmehl, Thomas
通讯作者: Schmehl, Thomas